PLEASANTON, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that Mark Foley, President and Chief Executive Officer, and Patrick F. Williams, Senior Vice President and Chief Financial Officer, are scheduled to present at the 31 st Annual J.P. Morgan Healthcare Conference.
|Event: 31st Annual J.P. Morgan Healthcare Conference|
|Date: Thursday, January 10, 2013|
|Time: 3:30 p.m. ET/12:30 p.m. PT|
An audio web cast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's web site at www.coolsculpting.com. A replay of the presentation will be available for 30 days.
About ZELTIQZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
CONTACT: Patrick F. Williams ZELTIQ Aesthetics, Inc. SVP and Chief Financial Officer 925-474-2546 Nick Laudico / Amy Glynn The Ruth Group 646-536-7030 / 7023 email@example.com firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts